Inhibitex Announces Data Presentation at the 60th Annual Meeting of the American Association for the Study of Liver Diseases ...

Inhibitex, Inc. (NASDAQ: INHX) announced today that a poster presentation describing preclinical data on INX-189, the lead compound from its HCV nucleotide polymerase inhibitor program, will be presented by Dr. Joseph M. Patti, Chief Scientific Officer and Senior Vice President of R&D, at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. The full abstract can be viewed at the AASLD website at www.aasld.org.

The poster (#1611 Patti, et al), entitled “Pharmacological Properties and In Vitro Characterization of INX-189, a Liver Targeted Phosphoramidate Nucleoside Analogue Inhibitor of NS5b” will be presented in the HCV Therapy: Preclinical and Early Clinical Development session from 8:00 am – 1:00 pm on Tuesday, November 3rd, 2009.

About HCV and Protides

Hepatitis C is a disease of the liver caused by the hepatitis C virus (HCV). It is estimated that approximately 4 million Americans and 170 million individuals worldwide are infected with HCV. HCV can cause chronic liver disease, cirrhosis and cancer, and is the leading cause of liver transplant in the United States. Inhibitex is developing a series of proprietary phosphoramidates, or protide nucleoside inhibitors, that target the RNA-dependent RNA polymerase (NS5b) of HCV. Protides are designed to by-pass the rate limiting first step in the formation of the active nucleoside triphosphate. INX-189 is a protide of a 2’-C-methyl guanosine analogue. The Company believes that its protides possess several pharmacological advantages over nucleosides alone and potentially other nucleotide prodrugs. These advantages include greater potency, a rapid conversion of the protide into its active form in the liver, and potentially less toxicity due to reduced systemic exposure of the nucleoside.

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on developing products to treat serious infectious diseases. In addition to INX-189, the Company’s pipeline includes FV-100, its clinical-stage nucleoside analogue in Phase II development for the treatment of herpes zoster (shingles). The Company has also licensed the use of its proprietary MSCRAMM® protein technology to Wyeth for the development of staphylococcal vaccines.

For additional information about the Company, please visit www.inhibitex.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than historical facts included in this press release, including statements regarding the Company’s belief that its protides possess several pharmacological advantages over nucleosides alone and potentially other nucleoside prodrugs, are forward looking statements. These results and expectations may not be achieved in the future and various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including the risk of: the Company not obtaining regulatory approval on a timely basis, or at all, to advance the development of INX-189 into clinical trials; the results of ongoing or future preclinical studies of INX-189 not supporting its further development; obtaining, maintaining and protecting the intellectual property incorporated into and supporting the commercial viability of the Company’s product candidates; and other cautionary statements contained elsewhere herein and in its Annual Report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission, or SEC, on March 23, 2009 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2009 as filed with the SEC on August 12, 2009. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.

There may be events in the future that the Company is unable to predict accurately, or over which it has no control. The Company's business, financial condition, results of operations and prospects may change. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information. The Company qualifies all of the information contained in this press release, and particularly its forward-looking statements, by these cautionary statements.

Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.

Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024